San Mateo, CA – According to filings with the U.S. Securities and Exchange Commission, Rakuten Medical is raising $291,010,708.00 in new funding. Sources indicate as part of senior management President, Takashi Toraishi played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Rakuten Medical
Rakuten Medical, Inc. is a global biotechnology company developing precision, cell-targeting investigational therapies on its IlluminoxTM platform, which, in pre-clinical studies have shown to lead to rapid and selective cell killing and tumor necrosis. Illuminox therapies have not yet been approved as safe or effective by any regulatory authority. Rakuten Medical is committed to its mission to conquer cancer and aims to realize a society where cancer patients can lead fulfilling lives. Headquartered in the United States, Rakuten Medical has 6 locations in 5 countries, including Japan, the Netherlands, Germany and Taiwan.

To learn more about Rakuten Medical, visit http://rakuten-med.com/

Contact:
Takashi Toraishi, President
858-925-5619
takashi.toraishi@rakuten-med.com
https://www.linkedin.com/in/takashitoraishi/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved